ECRG4 and type 2 diabetes mellitus: Recognition of ECRG4 as an important regulator of early neutrophil recruitment, and discovery of its deficiency in T2DM, positions this pathway as a potential therapeutic target, as restoring adequate early neutrophil responses in diabetic injury and infection may prevent more severe infections and correct impaired wound healing.